HAVCR2 and cancer: Blocking the pathway of TIM-3/Gal-9 binding may break the “depletion phenomenon” of T cells, and a combination of two monoclonal antibodies, anti-PD-1 and anti-TIM-3, can synergistically break the drug-resistant TIME, which is a promising novel cancer immunotherapy regimen (23).